Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$51.24M+426900.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Richard Gerald Adcock
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 688
- Beta
- 0.13
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -10.18
Financials
Revenue
$51.24M+426900.0%Net Income
$-230.38MEBITDA
$-221.58MFree Cash Flow
$-70.03MEPS (diluted)
$-0.22Shares Outstanding (diluted)
1.05B+219.5%Operating Expenses
$108.32MCash & Debt
$357.37MReturn of Capital
$0.00Revenue by Segment (annual)
$113.29MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $113.29M | $-351.40M | $-0.38 |
| 2024 | $14.74M | $-413.56M | $-0.59 |
| 2023 | $622.0K | $-583.20M | $-1.15 |
| 2022 | $240.0K | $-416.57M | $-1.04 |
| 2021 | $934.0K | $-346.79M | $-0.89 |
| 2020 | $605.0K | $-221.85M | $-0.59 |
| 2019 | $43.0K | $-65.79M | $-0.42 |
| 2018 | $47.0K | $-96.23M | $-0.30 |
| 2017 | $45.0K | $-96.42M | $-0.30 |
| 2016 | $44.0K | $-120.81M | $-0.37 |
| 2015 | $236.0K | $-236.88M | $-0.73 |
| 2014 | $641.0K | $-6.21M | $-0.02 |
| 2013 | $600.0K | $-2.05M | $-0.01 |
Valuation
IBRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
110+10.00%Social Signal Score
Mentions (6)
- Newsdefenseworld.net·2d ago·Positive
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of “Moderate Buy” from Brokerages ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The
View source ↗ - Newsbenzinga.com·8d ago·Neutral
ImmunityBio Stock Jumps: What's Going On? ImmunityBio Inc. (NASDAQ:IBRX) shares are soaring Friday, extending a steadily rising pattern that's played out over the past several months.
View source ↗ - News (RSS)yahoo·17d ago·Neutral
ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%
View source ↗ - Newszacks.com·22d ago·Neutral
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last? ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗ - News (RSS)seekingalpha·37d ago·Positive
ImmunityBio: None Of The Moonshots Is Priced In
View source ↗ - News (RSS)seekingalpha·45d ago·Neutral
ImmunityBio: ANKTIVA Is Real, The Valuation Isn't
View source ↗
Earnings
Tue, Nov 3(in 3 weeks)
Consensus estimate $-0.08 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-0.22 vs $-0.08miss
- Thu, May 7$-0.62 vs $-0.08miss
- Mon, Feb 23$-0.06 vs $-0.08beat
- Tue, Nov 4$-0.07 vs $-0.10beat
- Tue, Aug 5$-0.10 vs $-0.10beat
- Mon, May 12$-0.15 vs $-0.12miss
Estimates and results for IBRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IBRX officers and directors.
- Bought
- —
- Sold
- $8.4m
0 trades
14 trades
- Cohen Cherylsold
- Selecky Christobelsold
- Selecky Christobelsold
- Selecky Christobelsold
- Simon Barry J.sold
- Simon Barry J.sold
- Simon Barry J.sold
- Selecky Christobelsold
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.